Lyra Therapeutics, INC. (LYRA) — 10-Q Filings

10-Q Filings (6)

• Lyra's Losses Narrow Amidst R&D Cuts, Going Concern Doubts Persist — Nov 12, 2025 Risk: high
  Lyra Therapeutics, Inc. (LYRA) reported a net loss of $5.98 million for the three months ended September 30, 2025, a significant improvement from the $11.87 mil
• Lyra Therapeutics Navigates Restructuring Amidst Zero Revenue — Aug 12, 2025 Risk: high
  Lyra Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss f
• Lyra Therapeutics Files Q1 2025 10-Q — May 6, 2025 Risk: medium
  Lyra Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported on its financial position and operations, including details on c
• Lyra Therapeutics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Lyra Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and results of operations, incl
• Lyra Therapeutics Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  Lyra Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial activities, including details related to its "
• Lyra Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — Apr 30, 2024 Risk: medium
  Lyra Therapeutics, Inc. (LYRA) filed a Quarterly Report (10-Q) with the SEC on April 30, 2024. Lyra Therapeutics, Inc. filed a 10-Q report for the period ending

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX